Glaukos Corporation Announces Third Quarter 2019 Financial Results
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2019. Key highlights include: Achieved 33% net sales growth to $58.5 million in the third quarter of 2019, compared to $43.9 million in the third quarter of 2018. Reported gross margin of appr